Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
144.00    -1.00 (-0.69%)
Bid:
144.00
Ask:
145.00
Spread: 1.00 (0.694%)
Market Cap: £113.00m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Statement

14 Jan 2021 07:00

RNS Number : 6127L
Xaar PLC
14 January 2021
 

Xaar plc

 

Trading update 

 

Xaar plc ("Xaar", "the Group" or "the Company"), the leading inkjet printing technology, today announces a trading update for the year ended 31 December 2020.

 

TRADING

 

The Board is pleased to announce that, with the on-going successful implementation of the new strategy, trading was in line with its expectations. Revenue for the year was approximately £48m and in line with that recorded in FY2019.

 

The Printhead business continues to perform well with continued success in winning new customers. The customer-centric approach and focus on markets in which we have a competitive advantage is driving new business wins and seeing customers continue to re-engage. Additionally, our ImagineX platform is being successfully rolled out with a targeted product roadmap and clear growth opportunities ahead.

 

Despite the impact by COVID-19, our Product Print Systems business (EPS) has made progress with the strategy of developing a modular approach to products and, following the successful implementation of operational changes, the business is well placed for the future.

 

We have made further progress with product development and testing in Xaar 3D, despite continued COVID-19 related delays, and we continue to work closely with Stratasys to optimise the approach to commercialisation of the product range. 

 

BALANCE SHEET AND LIQUIDITY

 

The Group retains a strong balance sheet and cash position. Cash and cash equivalents at 31 December 2020 were £20.2m. This was driven by positive operational cash generation in both Printhead and EPS, as well as maintaining a strong focus on cash and disciplined cost controls.

 

CURRENT TRADING AND OUTLOOK

 

Despite the most recent COVID-19 lockdown, with pro-active management, we have maintained operational performance. Whilst COVID-19 continues to represent a key risk the order book remains strong with a positive pipeline. We continue to rigorously review opportunities available in the market, remaining focused on our strategy, and are on-track to return to profitability and growth.

 

 

John Mills, Chief Executive Officer, commented:

 

"We are very pleased with performance for the year which is a testament to the efforts of the team in extraordinary circumstances. We are one year into delivering our strategy and it is clearly having a positive impact, notably as existing customers continue to engage, and we are winning new business. We remain excited by the future and will remain disciplined in delivering long-term sustainable growth."

 

Enquiries:

 

Xaar plc

 

Ian Tichias, Chief Finance Officer

& Company Secretary

+44 (0) 1223 423 663 

John Mills, Chief Executive Officer

 

 

 

Tulchan Communications

James Macey White

Giles Kernick

Tom Blundell

 

 

 

+44 (0) 207 353 4200

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDXLFFFFLFBBV
Date   Source Headline
2nd Jun 202612:58 pmRNSTotal Voting Rights
28th May 20269:18 amRNSResult of AGM
6th May 20267:00 amRNSDirector/PDMR Shareholding
5th May 202611:36 amRNSHolding(s) in Company
30th Apr 20264:44 pmRNSHolding(s) in Company
16th Apr 20269:00 amRNSPublication of Annual Report and Notice of AGM
1st Apr 20263:43 pmRNSHolding(s) in Company
24th Mar 20267:05 amRNSFinal Results
23rd Mar 20263:33 pmRNS-RInvestor Presentation via Investor Meet Company
2nd Mar 20262:44 pmRNSTotal Voting Rights
14th Jan 20267:00 amRNSTrading Statement
5th Jan 202612:28 pmRNSTotal Voting Rights
5th Dec 20251:15 pmRNSHolding(s) in Company
1st Dec 202512:15 pmRNSTotal Voting Rights
24th Nov 202511:00 amRNSDirector/PDMR Shareholding
3rd Nov 20252:00 pmRNSTotal Voting Rights
21st Oct 20254:15 pmRNSDirector/PDMR Shareholding
13th Oct 20253:20 pmRNSHolding(s) in Company
2nd Oct 202511:10 amRNSDirector/PDMR Shareholding
2nd Oct 20258:50 amRNSDirector/PDMR Shareholding
1st Oct 20255:00 pmRNSDirector/PDMR Shareholding
1st Oct 20253:30 pmRNSTotal Voting Rights
1st Oct 202512:04 pmRNSTRADING UPDATE and NOTICE OF RESULTS
1st Sep 20254:30 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNS2025 INTERIM RESULTS
5th Aug 20257:00 amRNSBoard changes
1st Aug 20253:45 pmRNSTotal Voting Rights
14th Jul 202510:00 amRNSNotice of Interim Results
7th Jul 20253:30 pmRNSBlock listing Interim Review
2nd Jul 20253:30 pmRNSTotal Voting Rights
30th Jun 20252:00 pmRNSDirector/PDMR Shareholding
3rd Jun 202510:00 amRNSTotal Voting Rights
28th May 20253:30 pmRNSResult of AGM
21st May 20251:00 pmRNSHolding(s) in Company
7th May 20253:30 pmRNSNotification of Transactions of Directors & PDMRs
2nd May 202510:30 amRNSTotal Voting Rights
15th Apr 20251:15 pmRNS2024 Annual Report and Notice of AGM
11th Apr 202512:00 pmRNSHolding(s) in Company
1st Apr 20254:15 pmRNSHolding(s) in Company
1st Apr 20253:30 pmRNSTotal Voting Rights
31st Mar 20253:45 pmRNSNotification of Transactions of Directors & PDMRs
31st Mar 20251:10 pmRNSHolding(s) in Company
28th Mar 202511:30 amRNSHolding(s) in Company
27th Mar 202511:00 amRNSHolding(s) in Company
25th Mar 20255:00 pmRNSNotification of Transactions of Directors & PDMRs
25th Mar 20257:00 amRNSFinal Results
5th Mar 202511:30 amRNSTotal Voting Rights
19th Feb 202510:30 amRNSHolding(s) in Company
10th Feb 202511:00 amRNSHolding(s) in Company
5th Feb 20254:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.